Summary
On March 30, 2026, Xeris Biopharma Holdings Inc saw an insider sale when director James Aloysius Brady disposed of 10,834 shares of the company's common stock. The transaction, carried out under a pre-arranged Rule 10b5-1 trading plan, had a weighted average sale price of $5.5414 and totaled $60,035.
Transaction details
The individual trades that comprised the filing ranged in price from $5.290 to $5.630 per share. After the sale completed, Brady's direct holdings in Xeris Biopharma stood at 89,166 shares. The sale was recorded as executed through the 10b5-1 plan, indicating it followed previously established instructions rather than an ad hoc decision reported on the filing.
Market reaction and valuation context
Since the March 30 sale, Xeris's share price has risen to $6.04, reflecting a 14% appreciation over the prior week. According to InvestingPro analysis, the stock is trading near its Fair Value, although analysts' price targets show a wide range from $8 to $18. Investors seeking deeper company analysis can access a Pro Research Report on XERS, one of more than 1,400 U.S. equities covered by the service.
Recent financial performance and analyst stance
Xeris reported stronger-than-expected fourth-quarter 2025 results. Earnings per share came in at $0.06, versus analyst expectations of $0.02, which represents a 200% surprise relative to the consensus estimate. Revenue for the quarter totaled $85.8 million, above the anticipated $81.38 million. In a separate analyst development, Barclays reiterated its Overweight rating on Xeris Pharmaceuticals and kept a $9.00 price target.
In its commentary, Barclays noted that the company's market capitalization is currently below $1 billion and suggested that this valuation may not fully reflect a projected $4 billion peak sales opportunity. Those observations form part of the backdrop to the stock's recent movement and the range of analyst price targets.
What the record shows
The publicly filed transaction data records a director sale of 10,834 shares at a weighted average of $5.5414 on March 30, 2026, with trade prices between $5.290 and $5.630, leaving James Aloysius Brady with 89,166 shares post-transaction. The sale was implemented under a Rule 10b5-1 trading plan. The company also reported a notable fourth-quarter earnings and revenue beat for 2025, and Barclays maintained an Overweight rating with a $9 target.
This piece presents the transaction and recent company results without additional interpretation beyond the information contained in regulatory filings, analyst notes, and reported financial results.